Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M873Revenue $M15.0Net Margin (%)-258.4Z-Score6.3
Enterprise Value $M327EPS $-1.8Operating Margin %-220.1F-Score4
P/E(ttm))0Cash Flow Per Share $-0.8Pre-tax Margin (%)-258.4Higher ROA y-yN
Price/Book5.310-y EBITDA Growth Rate %0Quick Ratio5.8Cash flow > EarningsY
Price/Sales27.15-y EBITDA Growth Rate %11.8Current Ratio5.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-33.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-43.1Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M46.6ROI % (ttm)148Gross Margin Increase y-yN

Gurus Latest Trades with TKMR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TKMRJean-Marie Eveillard 2013-06-30 Sold Out $4.28 - $5.05
($4.74)
$ 18.7575%Sold Out0
TKMRJean-Marie Eveillard 2013-03-31 Buy $4.35 - $5.44
($4.73)
$ 18.7575%New holding25,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TKMR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


TKMR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lutwyche, PeterDirector or Senior Officer of Insider or Subsidiar 2014-12-01Sell18,000$18.434.67 view
Phillips, Peggy VanSiceDirector 2014-06-19Buy5,000$13.641.84 view
Phillips, Peggy VanSiceDirector 2014-06-18Buy5,000$13.641.84 view
Jewell, DonaldDirector 2014-06-16Buy2,450$14.1436.42 view
Jewell, DonaldDirector 2013-08-06Buy300$6.09216.75 view
Jewell, DonaldDirector 2013-08-06Buy500$6.1216.23 view
Jewell, DonaldDirector 2013-08-06Buy400$6.09216.75 view
Jewell, DonaldDirector 2013-08-06Buy400$6.1216.23 view
Murray, Mark JosephSenior Officer 2013-04-16Buy5,000$4.6319.35 view
Jewell, DonaldDirector 2013-03-12Buy1,200$4.44334.46 view

Press Releases about TKMR :

    Quarterly/Annual Reports about TKMR:

    News about TKMR:

    Articles On GuruFocus.com
    Tekmira Pharmaceuticals Gets Mixed Ratings After Ebola Drug Updates Nov 11 2014 
    Ebola: Is The Cure Out There? Oct 14 2014 
    Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 


    More From Other Websites
    The Zacks Analyst Blog Highlights: Medicines Co., Tekmira, GW Pharmaceuticals, Biogen and Alexion -... Apr 16 2015
    Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label... Apr 15 2015
    Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug Apr 14 2015
    Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog Apr 13 2015
    Maxim Analyst Issues Update On Tekmira's Ebola Research Development Apr 13 2015
    Tekmira gets nod for more Ebola drug testing Apr 10 2015
    Tekmira will resume safety study of Ebola drug within weeks Apr 10 2015
    Tekmira will resume safety study of Ebola drug within weeks Apr 10 2015
    FDA modifies partial clinical hold on Tekmira Ebola study Apr 10 2015
    Tekmira Approved to Continue Ebola Treatment Clinical Trials Apr 10 2015
    FDA Modifies Partial Clinical Hold on Tekmira's TKM-Ebola IND to Allow Multiple Dosing of Healthy... Apr 10 2015
    TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 10 2015
    FDA Modifies Partial Clinical Hold on Tekmira's TKM-Ebola IND to Allow Multiple Dosing of Healthy... Apr 10 2015
    Ebola Finances Coming Back in the News Mar 31 2015
    Tekmira Pharmaceuticals Rally Fades After Ebola Diagnosis In Guinea Mar 30 2015
    TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 26 2015
    Tekmira Presents Preclinical Results Demonstrating Super-Additive Effects on Plasma Triglyceride... Mar 25 2015
    Tekmira Presents Preclinical Results Demonstrating Super-Additive Effects on Plasma Triglyceride... Mar 25 2015
    TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 25 2015
    Tekmira Announces Completion of Underwritten Public Offering of Common Shares Mar 25 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK